Luc-Matthieu Fornecker, MD, PhD: Risks and Benefits of BV + AVD in Treatment-Naive Hodgkin Lymphoma

In the multicenter BREACH trial, adding brentuximab vedotin to AVD chemotherapy in patients with unfavorable, early-stage Hodgkin lymphoma led to higher rates of PET negativity, but, as Dr. Fornecker reported, increased toxicity.

SHARE